TRT is looking to partner with coffee and food processing companies to help bring this technology to use at an industrial scale. TRT CEO John Warlick relays the position of his company when he says, “I am very pleased and excited about this patent. It gives us the opportunity to do business without having to deal with the complicated and lengthy FDA processes. We are very eager to make use of this technology, and we look forward to finding partners to work with.”
We are very eager to make use of this technology, and we look forward to finding partners to work with.
TRT Announces Release of Patent that Opens New Doors for the Expansion of Shock Waves into Nonmedical Industries
Woodstock, GA, November 12, 2015 – Tissue Regeneration Technologies, LLC (TRT) today announces the issuance of patent number 9,060,525. With this new patent, TRT now owns the methodology of using shock wave technology to increase the amount of extract from cellular plant tissue. Modern industrial processes for extracting substances from plant cells are very inefficient and waste a lot of usable material. The use of shock waves, as patented by TRT, drastically increases the yield of such extraction processes.
Applications of Patent and Possibilities for TRT
This patent opens many avenues for TRT. First, the coffee industry is always looking for ways to get the most out of coffee beans. TRT research has shown that by applying shock waves to coffee beans during the brewing process, the beans’ cell membranes become more permeable, allowing more flavonoids and nutrients to be released. The United States imports more than $4 billion worth of coffee each year. Assuming that this TRT patented method can improve yield by 25%, this new method could potentially save coffee companies $1 billion annually.
Additionally, the process for extracting vitamins and minerals from plant cells can be greatly improved via the use of shockwaves by increasing the yield and decreasing the waste.
About TRT and Its Technologies
Tissue Regeneration Technologies, LLC, is the leader in the sales of acoustic wave technologies for indications that benefit from the proven biologic response of shock waves. TRT’s clear advantage over competitors in the shock wave industry is TRT’s dominant patent portfolio for unfocused SoftWave™ technology. SoftWave™ technology refers to unfocused acoustic waves that do not damage cells as competitors’ focused acoustic wave treatments might. TRT’s unfocused, patented technology works by using forces within waves to trick the body into starting an immune response. Effectively, SoftWave™ technology tells the body when and where to heal itself.
Additional advantages for TRT include time to market, management team experience, internationally approved products and distributors, relationships within the shock wave community, and a multiple of modern device platforms for different indications.
TRT is actively seeking strategic partners and investors to propel this amazing technology forward and to establish SoftWave™ therapy as the new standard of care in wound care, cardiology, and orthopedics. As a result of this patent, it is also looking for connections to place this technology in the food processing and coffee industries.